Brecken Moore
Nurse Practitioner · Sandy, UTNPI 1336830108
Payments from drug & device makers
Across 177 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$476
- Xeris Pharmaceuticals, Inc.$364
- Amgen$282
- Dexcom, Inc.$264
- Novartis$238
- Otsuka America Pharmaceutical, Inc.$171
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,70699%
- Entertainment$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 31 | $476 |
| Xeris Pharmaceuticals, Inc. | 18 | $364 |
| Amgen(2 entities) | 15 | $282 |
| Dexcom, Inc. | 3 | $264 |
| Novartis | 15 | $238 |
| Otsuka America Pharmaceutical, Inc. | 9 | $171 |
| Johnson & Johnson | 4 | $161 |
| Corcept Therapeutics | 6 | $135 |
| Tandem Diabetes Care, Inc. | 8 | $126 |
| Sanofi-aventis U.S. LLC | 5 | $117 |
| Antares Pharma, Inc. | 5 | $109 |
| Novo Nordisk | 7 | $106 |
| BETA Bionics, Inc. | 2 | $104 |
| Insulet Corporation | 1 | $103 |
| Recordati_rare_diseases_inc. | 5 | $88 |
| Ascensia Diabetes Care US Inc. | 4 | $73 |
| Amphastar Pharmaceuticals, Inc. | 4 | $72 |
| Boehringer Ingelheim | 3 | $68 |
| Alkermes, Inc. | 3 | $66 |
| AbbVie | 4 | $62 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| Chiesi USA, Inc. | 3 | $49 |
| Averitas Pharma Inc. | 1 | $48 |
| Radius Health, Inc. | 3 | $47 |
| Lundbeck LLC | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Boston Scientific | 1 | $27 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| Sandoz | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Optos, Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $21 |
| AstraZeneca | 1 | $17 |
| IBSA Pharma Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$247
- SPRAVATO$103
- Omnipod$103
How this compares
$3,728 in reported general payments places this provider in the 90th percentile of 979 nurse practitioner providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 145 | $193,840 |
| OzempicSemaglutide | 56 | $86,236 |
| JardianceEmpagliflozin | 56 | $65,772 |
| FarxigaDapagliflozin Propanediol | 20 | $32,853 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $31,461 |
| TrulicityDulaglutide | 24 | $30,006 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $29,621 |
| JanuviaSitagliptin Phosphate | 16 | $20,039 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $16,234 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $9,161 |
| Humalog Kwikpen U-100Insulin Lispro | 22 | $8,041 |
| NovologInsulin Aspart | 20 | $7,202 |
| Novolog FlexpenInsulin Aspart | 16 | $5,066 |
| Metformin Hcl | 84 | $1,276 |
| Testosterone Cypionate | 13 | $1,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $476 | $223,846169 claims |
| Novo NordiskOzempic, Novolog | $106 | $93,43876 claims |
| Boehringer IngelheimJardiance | $68 | $65,77256 claims |
| AstraZenecaFarxiga | $17 | $32,85320 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $117 | $16,23411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 979 nurse practitioner providers in Utah.
Other nurse practitioner in Sandy
- David GambleAmerican Fork$836K
- Julia BattenSalt Lake City$223K
- Stacie EganOgden$170K
- Traci AndreasonLehi$161K
- Geoffrey OsmondDraper$62K
- Trenton GraySouth Salt Lake$40K
- Kelsey FurrWest Jordan$21K
- Merin KinikiniSalt Lake City$19K
- Phillip BowmanSalt Lake City$18K
- Lynn LarsenOgden$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.